Answers are grounded in this paper and cite their sources.
Tigilanol tiglate is an oncolytic small molecule that is undergoing clinical trials. A recent study revealed the capacity of this pyroptosis inducer to elicit hallmarks of immunogenic cell death. In addition, intratumoral injection of tigilanol tiglate can sensitize subcutaneous cancers to subsequent immune checkpoint inhibitors targeting CTLA-4 alone or in combination with PD-1.
No takes yet. Share an insight, caveat, or question.
Pol et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: